12-Month Lobbying Summary - Consultant

Details Regarding the Identified Subject Matter

Subject matters	Details	Categories
Health	Engagement with officials on Bill S-280, An Act respecting a national framework on sickle cell disease, to discuss measures and initiatives to improve care and treatment of Canadians affected by sickle cell disease and increase public awareness of the disease.	Legislative Proposal, Bill or Resolution
Budget, Health	Federal programs and budgetary initiatives related to the Federal-Provincial-Territorial funding arrangements regarding pharmaceuticals.	Policies or Program
Health	Federally-funded Public Drug Plans, with respect to reimbursement for drug products for federal plan beneficiaries.	Policies or Program
Health	Guidelines, policies and programs related to regulatory and reporting functions of the Patented Medicine Prices Review Board	Policies or Program, Regulation
Health, Industry	Innovation, Science and Economic Development Canada and Innovation Agenda, Science and Technology Strategy, or other Government policy or program initiatives to support research and development activities in Canada.	Policies or Program
Health	Proposals to amend guidelines related to the operationalization of the legislation and regulations governing the Patented Medicine Prices Review Board	Policies or Program
Health	Regulatory amendments and/or guidelines related to the Food and Drugs Act Regulations and Health Canada review processes to implement an orphan drug regulatory framework.	Policies or Program, Regulation
Health	The development of a national pharmacare program, including the Canada Drug Agency, a national formulary and a rare diseases strategy	Policies or Program

• Subject matter details in previous versions

  Details Regarding the Identified Subject Matter

  Subject matters	Details	Categories
  Subject matters were not required to be associated with subject matter details when this content was submitted	Federal programs and budgetary initiatives related to the Federal-Provincial-Territorial funding arrangements regarding pharmaceuticals.	Policies or Program
  Subject matters were not required to be associated with subject matter details when this content was submitted	Federally-funded Public Drug Plans, with respect to reimbursement for drug products for federal plan beneficiaries.	Policies or Program
  Subject matters were not required to be associated with subject matter details when this content was submitted	Guidelines, policies and programs related to regulatory and reporting functions of the Patented Medicine Prices Review Board	Policies or Program, Regulation
  Subject matters were not required to be associated with subject matter details when this content was submitted	Innovation, Science and Economic Development Canada Innovation and Skills Strategy and other government policies and programs related to incentivizing research and development activities in Canada.	Policies or Program
  Subject matters were not required to be associated with subject matter details when this content was submitted	Innovation, Science and Economic Development Canada and Innovation Agenda, Science and Technology Strategy, or other Government policy or program initiatives to support research and development activities in Canada.	Policies or Program
  Subject matters were not required to be associated with subject matter details when this content was submitted	Proposals to amend guidelines related to the operationalization of the legislation and regulations governing the Patented Medicine Prices Review Board	Policies or Program
  Subject matters were not required to be associated with subject matter details when this content was submitted	Regulatory amendments and/or guidelines related to the Food and Drugs Act Regulations and Health Canada review processes to implement an orphan drug regulatory framework.	Policies or Program, Regulation
  Subject matters were not required to be associated with subject matter details when this content was submitted	The development of a national pharmacare program, including the Canada Drug Agency, a national formulary and a rare diseases strategy	Policies or Program

  Subject matters in previous versions

  • Economic Development
  • Health
  • Industry
  • Intellectual Property
  • International Trade
  • Science and Technology
  • Taxation and Finance

Government Institutions

• Finance Canada (FIN)
• Global Affairs Canada (GAC)
• Health Canada (HC)
• House of Commons
• Innovation, Science and Economic Development Canada (ISED)
• Justice Canada (JC)
• Patented Medicine Prices Review Board (PMPRB)
• Prime Minister's Office (PMO)
• Privy Council Office (PCO)
• Public Health Agency of Canada (PHAC)
• Senate of Canada
• Treasury Board Of Canada Secretariat (TBS)

Communication techniques

Communication techniques that have been used or are expected to be used in the course of the undertaking:

• Oral communication
• Written communication
• Arrange one or more meetings

Stephanie Levee, Consultant (Business address and contact information)

Public offices held